{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:38:18Z","timestamp":1787985498948,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jfo.2024.104348","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:58:36Z","timestamp":1730887116000},"page":"104348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive factors of early reactivation after \u0131ntravitreal ranibizumab in agressive retinopathy of prematurity"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-103X","authenticated-orcid":false,"given":"N.","family":"Sahinoglu-Keskek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-7424","authenticated-orcid":false,"given":"I.","family":"Akkoyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5505-8707","authenticated-orcid":false,"given":"B.","family":"Torer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-7339","authenticated-orcid":false,"given":"B.","family":"Cetinkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"G\u00fclcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0171-4200","authenticated-orcid":false,"given":"S.","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104348_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/IAE.0b013e3181cb6151","article-title":"Aggressive posterior retinopathy of prematurity","volume":"30","author":"Drenser","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104348_bib0215","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birth weight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2024.104348_bib0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3928\/01913913-20191030-01","article-title":"Combined vitrectomy and anti-VEGF treatment for stage 4 retinopathy of prematurity with extensive neovascular proliferation","volume":"57","author":"Chandra","year":"2020","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jfo.2024.104348_bib0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2024.104348_bib0235","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jfo.2024.104348_bib0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1120672119886989","article-title":"Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity","volume":"31","author":"Sahinoglu-Keskek","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10792-021-02004-8","article-title":"Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP","volume":"42","author":"Sen","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jfo.2024.104348_bib0255","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW Trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0260","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0265","doi-asserted-by":"crossref","first-page":"7518533","DOI":"10.1155\/2022\/7518533","article-title":"The role of thrombocyte parameters in retinopathy of prematurity development","volume":"2022","author":"Ozkaya","year":"2022","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jfo.2024.104348_bib0270","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00417-015-2972-8","article-title":"Relationship between mean platelet volume and retinopathy of prematurity","volume":"253","author":"Tao","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0275","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4274\/tjo.galenos.2020.01058","article-title":"Impact of platelet count in retinopathy of prematurity","volume":"50","author":"Sahinoglu Keskek","year":"2020","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pedneo.2017.11.001","article-title":"Platelet mass index can be a reliable marker in predicting the prognosis of retinopathy of prematurity in very preterm infants","volume":"59","author":"Korkmaz","year":"2018","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.jfo.2024.104348_bib0285","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1038\/s41433-020-01302-2","article-title":"Platelet distribution width is a predictive marker for development of severe retinopathy of prematurity","volume":"35","author":"Sahinoglu-Keskek","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2024.104348_bib0290","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0295","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104348_bib0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.9.8.43","article-title":"Ranibizumab population pharmacokinetics and free vegf pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial","volume":"9","author":"Fidler","year":"2020","journal-title":"Trans Vis Sci Tech"},{"key":"10.1016\/j.jfo.2024.104348_bib0305","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/medicina57050420","article-title":"Risk factors associated with retinopathy of prematurity in very and extremely preterm infants","volume":"57","author":"Bortea","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.jfo.2024.104348_bib0310","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000512282","article-title":"Decreased platelet counts and serum levels of VEGF-A, PDGF-BB, and BDNF in extremely preterm infants developing severe ROP","volume":"118","author":"Hellgren","year":"2021","journal-title":"Neonatology"},{"key":"10.1016\/j.jfo.2024.104348_bib0315","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0320","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Ar\u00e1mbulo","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"10.1016\/j.jfo.2024.104348_bib0325","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0330","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104348_bib0335","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrent of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0340","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104348_bib0345","doi-asserted-by":"crossref","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in zone II Stage 3+ after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0350","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","article-title":"Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104348_bib0355","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ophtha.2016.10.040","article-title":"Intraocular hemorrhages and retinopathy of prematurity in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study","volume":"124","author":"Daniel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104348_bib0360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104348_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-022-00364-6","article-title":"Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity","volume":"8","author":"Mirghorbani","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.jfo.2024.104348_bib0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.17772\/gp\/1562","article-title":"Alterations of peripheral blood cells in tubal ectopic pregnancy","volume":"84","author":"Turgut","year":"2013","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.jfo.2024.104348_bib0375","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IAE.0b013e3181cafc30","article-title":"Do platelets have a role in the pathogenesis of aggressive posterior retinopathy of prematurity?","volume":"30","author":"Vinekar","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104348_bib0380","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jaapos.2011.01.015","article-title":"Thrombocytopenia and retinopathy of prematurity","volume":"15","author":"Jensen","year":"2011","journal-title":"J AAPOS"},{"key":"10.1016\/j.jfo.2024.104348_bib0385","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/s00246-022-02847-7","article-title":"Platelet activation markers in children with pulmonary arterial hypertension associated with congenital heart disease","volume":"43","author":"Awad","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.jfo.2024.104348_bib0390","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1538-7836.2009.03584.x","article-title":"Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis","volume":"8","author":"Chu","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jfo.2024.104348_bib0395","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2008-06-159541","article-title":"Platelets actively sequester angiogenesis regulators","volume":"113","author":"Klement","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jfo.2024.104348_bib0400","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bph.12250","article-title":"Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin","volume":"170","author":"Etulain","year":"2013","journal-title":"Br J Pharmacol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224002936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224002936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:46:34Z","timestamp":1737650794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224002936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0181551224002936"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104348","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors of early reactivation after \u0131ntravitreal ranibizumab in agressive retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104348"}}